concizumab

mAbapprovedOrphan Drug FDA

Approved

Dec 20, 2024

Clinical trial activity

11 trials · 2 clinical orgs · 1 marketing orgs

Phase 1
4
Phase 2
5
Phase 3
3
Phase 4
0

Earliest trial started Oct 1, 2010 (NCT01228669)

Timeline

2010s

  1. Jan 1, 2010

    Novo Nordisk — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Novo Nordisk — Earliest Phase 2 Sponsor(trial)

  3. Oct 22, 2018

    Orphan Drug Designation

  4. Jan 1, 2019

    Novo Nordisk — Earliest Phase 3 Sponsor(trial)

2020s

  1. Dec 20, 2024

    Novo Nordisk — Earliest FDA Approval

  2. Dec 20, 2024

    Novo Nordisk — NDA Organization

  3. Dec 20, 2024

    Novo Nordisk — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewDec 20, 2024

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • concizumab
  • concizumab
  • concizumab
  • mab 2021
  • monoclonal antibody 2021
  • nnc172-2021

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06234813N/AApr 6, 2023University of Bordeaux
NCT05135559Phase 3Mar 24, 2022Novo Nordisk
NCT04082429Phase 3Oct 21, 2019Novo Nordisk
NCT04083781Phase 3Oct 21, 2019Novo Nordisk
NCT03196297Phase 2Aug 15, 2017Novo Nordisk
NCT03196284Phase 2Aug 15, 2017Novo Nordisk
NCT02490787Phase 1Sep 10, 2015Novo Nordisk
NCT01631942Phase 1Jun 1, 2012Novo Nordisk
NCT01555749Phase 1Mar 12, 2012Novo Nordisk
NCT01228669Phase 1Oct 1, 2010Novo Nordisk
NCT04921956N/ANovo Nordisk
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Novo NordiskFor profit101042010
University of BordeauxAcademic/Hospital1112023
2 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
Novo NordiskFor profitNDADec 20, 2024
Novo NordiskFor profitMKTGDec 20, 2024